 ESSA Pharma Inc. ESSA, or the Company NASDAQ: EPIX TSX-V: EPI, a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal third quarter ended June 30, 2020. All references to in this release refer to United States dollars, unless otherwise indicated. 